381 results on '"Patel, Bhavisha"'
Search Results
2. Role of allogeneic hematopoietic cell transplantation in VEXAS syndrome
3. Need of Carambola and Yunnan Pomegranate Seed in Controlling Proliferative Diseases
4. Nanoparticles
5. Cost Analysis of Target Lesion Revascularisation in Patients With Femoropopliteal In Stent Re-Stenosis or Occlusion: The COSTLY-TLR Study
6. Venous and arterial thrombosis in patients with VEXAS syndrome
7. Pathological fractures for the MRCS
8. Early activation of inflammatory pathways in UBA1-mutated hematopoietic stem and progenitor cells in VEXAS
9. Spectrum of clonal hematopoiesis in VEXAS syndrome
10. Differential diagnosis of bone marrow failure syndromes guided by machine learning
11. VEXAS syndrome, a new kid on the block of auto-inflammatory diseases: A hematologist's point of view
12. Predictors of clonal evolution and myeloid neoplasia following immunosuppressive therapy in severe aplastic anemia
13. Anti-COX-2 autoantibody is a novel biomarker of immune aplastic anemia
14. Biological Approaches to Nanoparticles Synthesis and their Applications in the Development Of Herbal Formulations
15. Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis
16. The Impact of Anemia on One-Year Amputation-Free Survival in Patients Undergoing Revascularization for Chronic Limb-Threatening Ischemia: A Retrospective Cohort Study
17. Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study
18. The Relationship Between Obesity and Amputation-free Survival in Patients Undergoing Lower-limb Revascularisation for Chronic Limb-threatening Ischaemia: A Retrospective Cohort Study
19. Efficacy of JAK1/2 inhibition in murine immune bone marrow failure
20. Skin Manifestations of VEXAS Syndrome and Associated Genotypes.
21. Opportunistic Infections, Mortality Risk, and Prevention Strategies in Patients With Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic (VEXAS) Syndrome.
22. What’s age got to do with it? A study of the implementation of the discharge medicines service for paediatric patients
23. Ahemolytic PNH (white cell PNH): Clinical features and implications of a distinct phenotype of paroxysmal nocturnal haemoglobinuria
24. Cost Analysis of Target Lesion Revascularisation in Patients With Femoropopliteal In Stent Re-Stenosis or Occlusion: The COSTLY-TLR Study
25. Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1
26. Immunologic effects on the haematopoietic stem cell in marrow failure
27. Deletion of the deISGylating enzyme USP18 enhances tumour cell antigenicity and radiosensitivity
28. Immune‐monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium.
29. Clonal haematopoiesis across the age spectrum of vasculitis patients with Takayasu's arteritis, ANCA-associated vasculitis and giant cell arteritis.
30. When to consider inherited marrow failure syndromes in adults
31. Granulocyte transfusions in severe aplastic anemia
32. Clonal haematopoiesis across the age spectrum of vasculitis patients with Takayasu’s arteritis, ANCA-associated vasculitis and giant cell arteritis
33. Use of flow cytometric light scattering to recognize the characteristic vacuolated marrow cells in VEXAS syndrome
34. Idiopathic gingival fibromatosis: a diagnostic dilemma.
35. "A Comprehensive Review on Selective Dual Inhibitor NSAID - Polmacoxib".
36. S184: SAFETY AND OUTCOMES FOLLOWING IMMUNOSUPPRESSIVE THERAPY WITH ATG/CYCLOSPORIN +/- ELTROMBOPAG FOR OLDER PATIENTS WITH SEVERE APLASTIC ANEMIA
37. S176: FUNCTIONAL AND ANTIGEN-SPECIFIC CHARACTERIZATION OF IMMUNE CELLS AT THE SINGLE-CELL LEVEL REVEALS CONVERGENCE OF ADAPTIVE AND INNATE IMMUNITY IN IMMUNE APLASTIC ANEMIA
38. Conditional survival and standardized mortality ratios of patients with severe aplastic anemia surviving at least one year after hematopoietic cell transplantation or immunosuppressive therapy
39. Alemtuzumab in relapsed immune severe aplastic anemia: Long‐term results of a phase II study
40. Abstract 2803: Pharmacokinetics and pharmacodynamics of the novel OMA1 activator BTM 3566 in a mouse model of diffuse large B-cell lymphoma
41. Lung Adenocarcinoma
42. List of Contributors
43. Efficacy of JAK1/2 inhibition in murine immune bone marrow failure
44. Acute Toxicity Sudy of Eladi Quatha: A Compound Ayurvedic Formulation.
45. Differential diagnosis of bone marrow failure syndromes guided by machine learning
46. Selecting Portable Ankle/Toe Brachial Pressure Index Systems for a Peripheral Arterial Disease Population Screening Programme: a Systematic Review, Clinical Evaluation Exercise, and Consensus Process
47. Granulocyte Transfusions As an Adjunctive Therapy in Severe Aplastic Anemia
48. Clonal Hematopoiesis in a Broad Age Spectrum of Systemic Vasculitis
49. Eosinophilia in Vexas Syndrome: Expanding Hematologic Phenotype
50. DNMT3A/TET2 Mutant Clonal Hematopoiesis in Vexas Syndrome Results in DNA Hypomethylation and Transcriptional Activation of WT1 and MPL Oncogenic Pathways
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.